Approximately every nine minutes, someone in the United States dies from a blood cancer, according to the Leukemia & Lymphoma ...

Continuous enrollment in Medicaid was associated with a lower rate of a late-stage lymphoma diagnosis in children and ...

An immunotherapy approach to treating advanced Hodgkin lymphoma may drastically increase patients’ chances of survival, including those as young as 12, according to a new clinical trial.

A Morgan Sherrill Family Benefit will be held from 4-8 p.m. on Saturday, Nov. 23, at Fines Creek Community Center.

July 22, 2024 — The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for ...

The study systematically characterized RILD using bronchoalveolar lavage and high-resolution CT in 321 patients, mostly with ...

Nkarta’s pivot from oncology to autoimmune disease has continued with the biotech halting work on its CD19-directed CAR NK in lymphoma to focus on lupus. Seven patients with heavily pretreated large B ...

DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...

Stephens initiates coverage on ADC Therapeutics (ADCT), highlighting Zynlonta's potential in second-line DLBCL and a ...

The N-AVD regimen showed improved progression-free survival and lower toxicity than BV-AVD in advanced Hodgkin lymphoma, ...

Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, ...